For a better experience of our website please update you web browser from IE11 to Microsoft Edge or an alternative modern browser such as Google Chrome. Thank you.

Author Archives: Arturs Lundbergs

Oligonucleotide stars of the future can be underpinned by the superb Amideus brand from Primopus AG.

Oligonucleotides moving from rare drug provision to wider population usage can be underpinned by affordable phosphoramidite provision. A bold statement becomes real with the 2021 approval of Inclisiran, used for the treatment of cardiovascular disease. A breadth of common diseases, including cardiovascular disease, oncology and metabolic disorders will respond to Oligonucleotide drug provision. Oligonucleotides because […]

Posted in News |

CPHI 2024

Planning has started and we look forward to CPHI in October. Booth preparations are underway and we look forward to meeting you all there.

Posted in Events |

TIDES Europe 2024

We will be attending TIDES Europe in November. If you are also attending and would like to arrange a meeting, get in contact today. We look forward to meeting you all there.

Posted in Events |

North America is expected to dominate the Phosphoramidite market over the next five years

The Phosphoramidite Market size is estimated at USD 1.13 billion in 2024 and is expected to reach USD 1.79 billion by 2029, growing at a CAGR of 6.42% in the next five years. The factors responsible for the growth of the phosphoramidite market include increasing synthetic nucleotide applications in therapeutics, growth in synthetic biology, and […]

Posted in News |

Primopus looks forward to the year ahead

Progress is being made in the multiple interest areas of our phosphoramidites brand, Amideus. We are fairly unique in having a dedicated team working on phosphoramidites for volume application for CDMO purposes. An increasing area of focus is Fmoc Amino Acids where important news will soon be released. We are meeting the various challenges in […]

Posted in News |

Primopus appreciates art, innovation and impetus

A big thank you to all our clients who attended our booth and our splendid CPHI event at the Picasso/Miro event. The splendid art is an inspiration to all those who appreciate creativity. So it is with our brand Amideus and its focus on phosphoramidites. You cannot simply think today that one region can supply […]

Posted in News |

A CDMO That is Ideally Placed to Meet the Rapidly Changing Pharma Supply Chain Thinking

Driven by a strong geo-political de-risking of overly dependent supply chain arrangements, a drastic rethinking about searching for and developing alternative options is underway in the pharma industry. This is evidenced by several leading companies defining new policies and the separation of activities from select countries. Primopus has been working diligently to repurpose the pharma […]

Posted in News |

Introducing Amideus™, our new Phosphoramidites brand for the Oligonucleotides market

Primopus reaches its first milestone towards becoming one of the largest phosphoramidites manufacturers in the world with Amideus. Marcel Velterop, Primopus CEO, says “the idea of producing bulk Phosporamidites emerged from a best-of-both-worlds strategy that combines our Swiss installed capacity of up to 250m3 with the massive capacity and broad chemistry base of our parent Deccan […]

Posted in News |

Primopus welcomes 7 new colleagues as part of its CDMO expansion plans in Switzerland

Primopus welcomes 7 new colleagues as part of its CDMO expansion plans in Switzerland and wishes everybody a happy, healthy 2023. During 2023 we expect our team to double in size as we start-up our new pilot plant during Q1 and commercial plant by Q4.

Posted in News |

Season’s Greetings to all

As we enter into this festive period, we would like to take this opportunity to wish all of our customers, friends and family all the best for 2023. 2022 has seen us rebrand as Primopus as we embark on the next chapter of the company. 2023 will be equally exciting as we continue to expand […]

Posted in News |